Live Breaking News & Updates on அடுத்தது ஜெநரேஶந் ப்ரோபிஒடிக்ஸ்

Stay updated with breaking news from அடுத்தது ஜெநரேஶந் ப்ரோபிஒடிக்ஸ். Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Sequentia collaborated with Nextbiomics


On April 12, 2021, Sequentia Biotech, a Spanish omics company, and NextBiomics, a biotech company involved in the research and development of Next Generation Probiotics and a spin-off of the Federico II University of Naples, announced the filing of a patent application for a bacterial vaccine against the COVID-19 syndrome.
By engineering the probiotic Escherichia Coli Nissle 1917 expressing the SARS-CoV-2 Spike protein, it was possible to obtain an innovative model of immunization against COVID-19 by stimulating the intestinal immune system”,
Giovanni Sarnelli
“The NEXBIOMICS vaccine is similar to others that have been already authorized (Pfizer, Moderna, AstraZeneca, Reithera, Johnson & Johnson) in that it stimulates the immune response against the Spike protein that the Coronavirus uses to infect cells, but it differs from them because it uses a probiotic bacterium as a vector, which is already on the market and being widely used for other purposes. ....

Walter Sanseverino , Sequentia Biotechmay , Francesco Campobasso , Giuseppe Esposito , Giovanni Sarnelli , University Of Naples Federico , Sapienza University Of Rome , Federico Ii University Of Naples , From Sequentia Biotechmay , Sequentia Biotech , Next Generation Probiotics , Escherichia Coli Nissle , Sapienza University , New Generation Probiotics , Naples Federico , Immune Response , Immune System , Next Generation , Ars Cov 2 , Spike Protein , பிரான்செஸ்கோ காம்பொபஸ்ஸோ , கியூசெப் எஸ்போசிட்டோ , பல்கலைக்கழகம் ஆஃப் நேபிள்ஸ் ஃபெடரீகொ , சாபிென்ச பல்கலைக்கழகம் ஆஃப் ரோம் , ஃபெடரீகொ ீ பல்கலைக்கழகம் ஆஃப் நேபிள்ஸ் , அடுத்தது ஜெநரேஶந் ப்ரோபிஒடிக்ஸ் ,